New diabetes drug shows promise in early trial
NCT ID NCT07160257
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This early-stage study tests whether a new drug, maridebart cafraglutide, can help the body use insulin better in people with type 2 diabetes. About 57 adults aged 18 to 70 who are already taking metformin will receive either the drug or a placebo. The main goal is to measure changes in insulin sensitivity after 25 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ProSciento, Inc. - Main Clinic
RECRUITINGChula Vista, California, 91911-1350, United States
Conditions
Explore the condition pages connected to this study.